References
- Conlon R, Saheb H, Ahmed IIK. Glaucoma treatment trends: a review. Can J Ophthalmol. 2017;52(1):114–124. doi:10.1016/j.jcjo.2016.07.013.
- Lusthaus JA, Goldberg I. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation. Expert Opin Drug Saf. 2017;16(9):1071–1078. doi:10.1080/14740338.2017.1346083.
- Hopf S, Mercieca K, Pfeiffer N, Prokosch-Willing V. Brimonidine-associated uveitis – a descriptive case series. BMC Ophthalmol. 2020;20(1):1–7. doi:10.1186/s12886-020-01762-w.
- Manabe Y, Sawada A, Mochizuki K. Corneal sterile infiltration induced by topical use of ocular hypotensive agent. Eur J Ophthalmol. 2020;30(5): NP23–NP25. doi:10.1177/1120672119850080.
- Maruyama Y, Ikeda Y, Yokoi N, et al. Severe corneal disorders developed after brimonidine tartrate ophthalmic solution use. Cornea. 2017;36(12):1567–1569. doi:10.1097/ICO.0000000000001370.
- Kasuya Y, Sano I, Makino S. Interstitial keratitis with lipid keratopathy mimicking corneal opacity induced by Brimonidine tartrate eye drops. Klin Monbl Augenheilkd. 2020;237(12):1466–1467. doi:10.1055/a-1265-7105.
- Tsujinaka A, Takai Y, Inoue Y, Tanito M. A case of bilateral deep stromal corneal opacity and vascularization after use of multiple antiglaucoma medications including brimonidine tartrate ophthalmic solution. Acta Ophthalmol. 2019;97(6):e948–e949. doi:10.1111/aos.14008.
- Watts P, Hawksworth N. Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure. Eye. 2002;16(2):132–135. doi:10.1038/sj/eye/6700053.
- Sharma T, Salmon JF. Hypotony and choroidal detachment as a complication of topical combined timolol and dorzolamide. J Ocul Pharmacol Ther. 2007;23(2):202–205. doi:10.1089/jop.2006.0050.
- Fineman M, Katz L, Wilson R. Topical dorzolamide-induced hypotony and ciliochoroidal detachment in patients with previous filtration surgery. Arch Opthalmol. 1996;114(8):1031–1032. doi:10.1001/archopht.1996.01100140239041.